Gilead's remdesivir prevents lung damage in COVID-19 study on monkeys

Gilead Sciences Inc's antiviral drug remdesivir prevented lung disease in macaque monkeys infected with the new coronavirus, according to a study published in the journal Nature on Tuesday.